Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study
Abstract
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in patients undergoing percutaneous coronary intervention and determine factors affecting clopidogrel resistance.
METHODS: The subjects were 119 patients who underwent percutaneous coronary intervention (PCI) and had given loading dose of 600 mg clopidogrel. Blood samples were taken at 6 hour after clopidogrel loading dose. Platelet aggregation was measured by LTA and VerifyNow.
RESULTS: LTA and VerifyNow assay showed fair agreement with Kappa=0.270, p=0.001. The proportion of resistance to clopidogrel using VerifyNow was 21.8% and LTA was 47.1%. Patients with diabetes melitus were more likely to develop clopidogrel resistance than patients without diabetes (OR of 7.67; 95% CI: 1.87-31.50; p=0.005).
CONCLUSION: The ability of LTA and VerifyNow in detecting clopidogrel resistance were not comparable. Multivariate analysis results for VerifyNow shows diabetes mellitus as the greatest predictors of clopidogrel resistance.
KEYWORDS: agreement, clopidogrel resistance, LTA, predictor, VerifyNow
Full Text:
PDFReferences
Granger CB, Bates ER, Jollis JG, Antman EM, Nichol G, O’Connor RE, et al. Improving care of STEMI ini the United States 2008 to 2012: A report from the American Heart Association Mission: Lifeline program. J Am Heart Assoc. 2019; 8: e008096, CrossRef.
Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for themanagement of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119-77, CrossRef.
Tran H, Mehta S, Eikelboom J. Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vasc Health Risk Manag. 2006; 2: 379-87, CrossRef.
Wiviott S, Antman E. Clopidogrel resistance: A new chapter in fast-moving story. Circulation. 2004; 109: 3064-7, CrossRef.
Saraf S, Bensalha I, Gorog D. Antiplatelet resistance-does it exist and how to measure it? Clin Med Cardiol. 2009; 3: 77-91, PMID.
Yaseen I, Farhan H, Abbas H. Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. Eur J Hosp Pharm. 2019; 26: 113-6, CrossRef.
Akturk I, Caglar F, Erturk M, Tuncer N, Yalcın A, Surgit O, et al. Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. Appl Thromb. 2014; 20: 749-54, CrossRef.
Koshy S, Salahuddin S, Karunakaran B, Nalakath S, Bhaskaran J, Haridas P, et al. Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease. Heart Asia. 2014; 6: 159-62, CrossRef.
Van Werkum J, Harmsze A, Elsenberg E, Bouman H, Ten Berg J, Hackeng C, et al. The use of the Verify Now system to monitor antiplatelet therapy: A review of current evidence. Platelet. 2008; 19: 479-88, CrossRef.
Westgard JO [Internet]. Madison: Westgard QC; © 2019.The Comparison of Methods Experiment [cited 2020 Aug 10]. Available from: https://www.westgard.com/.
Helena Laboratories. Helena Platelet Aggregation Reagents, Cat. No. 5366, 5367, 5368, 5369. Beaumont; Helena Laboratories; n.y, article.
Gurbel P, Antonino M, Bliden K, DiChiara J, Suarez T, Singla A, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets. 2008; 19: 595-604, CrossRef.
Accriva Diagnostic. VerifyNow System: User Manual. California: Accriva Diagnostic; 2008, article.
Millet ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018; 2018: 363, CrossRef.
Badan Litbangkes Kementerian Kesehatan RI. Hasil Utama Riskesdas 2018. Jakarta: Badan Litbangkes Kementerian Kesehatan RI; 2019, article.
Rumenta D. Proporsi dan faktor yang mempengaruhi resistensi klopidogrel pada pasien sindrom koroner akut dan/atau post intervensi koroner perkutan di RS Jantung dan Pembuluh Darah Harapan Kita [Thesis] Jakarta: Universitas Indonesia; 2016, article.
Vries MJA, Bouman HJ, Olie RH, Veenstra LF, Zwaveling SI, Verhezen PWM, et al. Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother 2017; 3: 11-7, CrossRef.
Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci 2013; 123: 143-54, CrossRef.
Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet 2015; 54: 147-66, CrossRef.
SuJun Feng, HuXiao Hui, LiCheng Yan. Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. Exp Ther Med. 2015; 9: 267-71, CrossRef.
Randriamboavonjy V, Fileming I. Insulin, insulin resistance and platelet signaling in diabetes. Diabetes Care. 2009; 32: 528-31, CrossRef.
Vlachojannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel Resistance: Current aspects and futute directions. HJC. 2010;52: 236-45, PMID.
DOI: https://doi.org/10.18585/inabj.v13i2.1477
Copyright (c) 2021 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
